A Post Hoc Analysis of Efficacy Data on Sarecycline in Hispanics with Acne from Two Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trials
Sarecycline is a novel, narrow-spectrum, third generation tetracycline class antibiotic approved by the Food and Drug Administration (FDA) for the treatment of moderate-to-severe acne in patients ages nine and older. Recently, focus has increased on whether treatment responses differ in acne in skin...
Saved in:
Main Authors: | Angela Yen Moore (Author), Kara Hurley (Author), Stephen Andrew Moore (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Effect of Sarecycline on the Acne Symptom and Impact Scale and Concerns in Moderate-to-Severe Truncal Acne in Open-Label Pilot Study
by: Angela Yen Moore, et al.
Published: (2023) -
Sarecycline: A Review of Preclinical and Clinical Evidence
by: Moore AY, et al.
Published: (2020) -
De novo design of pimarane diterpenoid compounds as potential alternatives to sarecycline for acne vulgaris treatment
by: Adeola Tawakalitu Kola-Mustapha
Published: (2023) -
Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8‐week, multicenter, double‐blind, randomized controlled study
by: Philip D. Harvey, et al.
Published: (2020) -
Acne Keloidalis Nuchae: A Multicenter Retrospective Study of 142 Hispanic Patients
by: Luis E. Sánchez-Dueñas, et al.
Published: (2024)